A key contact for transactional and regulatory healthcare issues is Goodwin, who handles matters at the intersection of technology, life sciences, private equity, and healthcare. The team advises on internal investigations, and structuring, developing, and commercialising AI technology. Boston-based co-head David Cappillo advises both healthcare and technology clients, while fellow Boston co-head Chris Wilson focuses on transactional matters. Co-head William Jackson, who is based in Washington DC, represents plaintiffs and defendants in IP, class action, and commercial healthcare-related disputes. Boston’s Miranda Hooker‘s clients include pharmaceutical and medical device companies and diagnostic laboratories. Philadelphia’s John Jones is informed in regulatory and transactional issues, while New York-based Roger Cohen focuses on healthcare M&A, capital markets, and financing transactions. Washington DC’s Ilene Albala specializes in FCA defense and litigation involving Anti-Kickback statutes and Stark Law. Nicole Aiken-Shaban joined the firm from Reed Smith LLP in February 2026.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Testimonials
Collated independently by Legal 500 research team.
‘Goodwin’s healthcare practice is distinguished by its ability to manage sophisticated healthcare transactions while staying closely grounded in the regulatory and operational realities of the industry. The team brings together strong M&A execution and practical healthcare regulatory insight, allowing them to structure complex deals efficiently and with confidence.’
- ‘Potential clients should know that the group excels at complicated deal structures and fast-moving transactions where healthcare regulations meaningfully affect risk and value. They are commercially minded, easy to work with, and effective at integrating regulatory considerations directly into deal strategy rather than treating them as an afterthought.’
- ‘Compared to other firms, Goodwin stands out for its balance of sophistication and pragmatism. The team communicates clearly, avoids unnecessary complexity, and focuses on solutions that move transactions forward. Strong collaboration across corporate and regulatory teams further enhances efficiency and consistency.’
‘The individuals we work with at Goodwin stand out for their judgment, commercial awareness, and ability to manage complex healthcare matters without unnecessary friction. They are practical, responsive, and focused on helping transactions move forward while managing regulatory risk.’
- ‘Chris Wilson in particular distinguishes himself through strong leadership, deep experience with sophisticated healthcare deals, and excellent judgment under pressure. He brings a calm, solutions-oriented approach to complicated structures and is highly trusted on matters where regulatory considerations are central to deal execution. The broader team reflects these same qualities, with associates who are thoughtful, engaged, and capable of operating at a high level in fast-moving transactions.’
‘Greg Demske and his 25+ years in the federal government provides invaluable expertise.’
Key clients
- Novo Holdings
- Webster Equity Partners
- InTandem Capital Partners
- Frazier Healthcare Partners
- Hospital for Special Surgery
- CenExel Clinical Research
- WHOOP
- Troy Medicare
- OpenEvidence, Inc.
Work highlights
Advised Novo Holdings A/S on the completion of its $16.5 billion all-cash acquisition of Catalent, Inc.
Advised CenExel Clinical Research and Webster Equity Partners in a $1.5 billion transaction transferring control of CenExel to BayPine.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
David Cappillo; William Jackson; Chris Wilson
Other key lawyers
Kirk Ogrosky; Greg Demske; Miranda Hooker; John Jones; Roger Cohen; Ilene Albala